As­traZeneca's Imfinzi fails blad­der can­cer tri­al — in pa­tient pop­u­la­tion cov­ered by FDA's 2017 ac­cel­er­at­ed ap­proval

A post-ap­proval com­mit­ment test­ing Imfinzi in a late-stage blad­der can­cer pop­u­la­tion has gone pear-shaped for As­traZeneca, as the check­point in­hibitor failed to help pa­tients live …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER